EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSMAMG00000001133
Gene Symbol: HTR2B
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSMAMG00000010903
Gene Symbol: HTR2CL1
3 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 3b

Ensembl ID : ENSMAMG00000002589
Gene Symbol: HTR3B
2 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSMAMG00000003749
Gene Symbol: HTR5AB
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMAMG00000007784
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSMAMG00000009703
Gene Symbol: HTR1B
3 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSMAMG00000018372
Gene Symbol: HTR1F
3 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSMAMG00000002560
Gene Symbol: HTR3A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSMAMG00000010057
Gene Symbol: HTR4
2 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSMAMG00000022613
Gene Symbol: HTR7
2 Cross references
196 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSMAMG00000016387
Gene Symbol: LOC113135411
3 Cross references
328 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSMAMG00000019460
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).